FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Molecular approaches to equine sarcoids.
Equine veterinary journal2020; 53(2); 221-230; doi: 10.1111/evj.13322

Molecular approaches to equine sarcoids.

Abstract: Sarcoids are the most commonly diagnosed skin tumours in equines. Bovine papillomaviruses (BPVs) are the primary causative agent of sarcoids. There has been intensive research to discover the molecular mechanisms that may contribute to the aetiopathogenesis of this disease and tumour suppressors and proto-oncogenes known to play a role in human neoplastic conditions have been investigated in equine sarcoids. Current approaches include the identification of gene expression profiles, characterising sarcoid and normal skin tissues, and an assessment of epigenetic alterations such as microRNA differential expression and DNA methylation status. This review focuses on selected groups of genes that contribute to the molecular mechanisms of sarcoid formation. These genes have the potential to complement current clinical examinations of equine sarcoid disease in diagnosis, prognosis, therapeutic response and screening.
© 2020 EVJ Ltd.
Get Full Text
Publication Date: 2020-08-03 PubMed ID: 32654178DOI: 10.1111/evj.13322Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores the molecular mechanisms behind equine sarcoids, common skin tumors in horses that are primarily caused by bovine papillomaviruses (BPVs). The study looks at specific genes and their roles in the formation of these sarcoids, in turn contributing to the understanding of diagnosis, prognosis, therapeutic response, and screening of the disease.

Molecular Mechanisms Behind Sarcoids

  • The main focus of this research article is equine sarcoids, which are the most common type of skin tumours found in horses. The key cause of these sarcoids is Bovine Papillomaviruses (BPVs).
  • The scientific community is investing heavily in research to uncover the molecular mechanisms that contribute to this disease’s cause and development. Tumour suppressors and proto-oncogenes, which are known to have a role in human neoplastic conditions, are investigated in relation to equine sarcoids.

Approach and Method of the Research

  • In their research, the scientists identify gene expression profiles specific to sarcoids. This enables better characterization of the tumorous and normal skin tissues in horses.
  • They also assess various epigenetic alterations such as microRNA differential expression and DNA methylation status. These are crucial elements that play a part in the development of sarcoids and other tumorous conditions.

Genes and Sarcoid Formation

  • The review focuses on select groups of genes that contribute to how sarcoids form. Understanding the genetics behind this can facilitate the development of treatments and preventive measures, potentially leading to a decrease in cases of equine sarcoids.

Implication of the Research

  • The findings from this study could have a substantial impact on the clinical examination of equine sarcoid disease. If these genes are better understood, they could augment diagnosis, assist in predicting disease progression (prognosis), aid in therapeutic response, and be utilized in screening processes.

Cite This Article

APA
Semik-Gurgul E. (2020). Molecular approaches to equine sarcoids. Equine Vet J, 53(2), 221-230. https://doi.org/10.1111/evj.13322

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 53
Issue: 2
Pages: 221-230

Researcher Affiliations

Semik-Gurgul, Ewelina
  • Department of Animal Molecular Biology, National Research Institute of Animal Production, Balice, Poland.

MeSH Terms

  • Animals
  • Bovine papillomavirus 1
  • Cattle
  • Cattle Diseases
  • Equidae
  • Horse Diseases / diagnosis
  • Horse Diseases / genetics
  • Horses
  • Papillomavirus Infections / veterinary
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / genetics
  • Skin Neoplasms / veterinary

References

This article includes 106 references
  1. Funiciello B, Roccabianca P. Equine Sarcoid. .
    doi: 10.5772/intechopen.91013google scholar: lookup
  2. Berruex F, Gerber V, Wohlfender FD, Burger D, Koch C. Clinical course of sarcoids in 61 Franches-Montagnes horses over a 5-7 year period. Vet Q 2016;36:189-96.
  3. Chambers G, Ellsmore VA, O'Brien PM, Reid SW, Love S, Campo MS. The association of bovine papillomavirus with equine sarcoids. J Gen Virol 2003;84:1055-62.
  4. Melkamu S, Chanie M, Asrat M. A review on equine sarcoid: current techniques employed insciences for diagnosis, prevention and control. Int J Adv Res Biol Sci 2018;5:155-64.
  5. Knottenbelt DC. A suggested clinical classification for the equine sarcoid. Clin Tech Equine Pract 2005;4:278-95.
  6. Studer S, Gerber V, Straub R, Brehm W, Gaillard C, Lüth A. Prevalence of hereditary diseases in three-year-old Swiss Warmblood horses. Schweiz Arch Tierheilkd 2007;149:161-71.
  7. Mohammed HO, Rebhun WC, Antczak DF. Factors associated with the risk of developing sarcoid tumours in horses. Equine Vet J 1992;24:165-8.
  8. Reid SW, Gettinby G, Fowler JN, Ikin P. Epidemiological observations on sarcoids in a population of donkeys (Equus asinus). Vet Rec 1994;134:207-11.
  9. Wobeser BK, Davies JL, Hill JE, Jackson ML, Kidney BA, Mayer MN. Epidemiology of equine sarcoids in horses in western Canada. Can Vet J 2010;51:1103-8.
  10. Broström H. Equine sarcoids. A clinical and epidemiological study in relation to equine leucocyte antigens (ELA). Acta Vet Scand 1995;36:223-36.
  11. Miller RI, Campbell RSF. A survey of granulomatous and neoplastic diseases of equine skin in North Queensland. Aust Vet J 1982;59:33-7.
  12. Marti E, Lazary S, Antczak DF, Gerber H. Report of the 1St International Workshop on equine sarcoid. Equine Vet J 1993;25:397-407.
  13. Piscopo SE. The complexities of sarcoid tumors. Equine Pract 1999;21:14-8.
  14. Foy JM, Rashmir-Raven AM, Brashier MK. Common equine skin tumors. Compend Contin Educ Pract Vet 2002;24:242-54.
  15. Scott DW, Miller WH. Neoplastic and nonneoplastic tumours - equine sarcoids. 2003;p. 719-31.
  16. Pascoe RR, Knottenbelt DC. Neoplastic conditions. 1999;p. 244-52.
  17. Taylor S, Haldorson G. A review of equine sarcoid. Equine Vet Educ 2013;25:210-6.
  18. Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 2008;19:243-54.
  19. Jackson C. The incidence and pathology of tumors of domesticated animals in South Africa. Onderstepoort J Vet Sci Anim Ind 1936;6:375-85.
  20. Lancaster WD. Apparent lack of integration of bovine papillomavirus DNA in virus-induced equine and bovine tumor cells and virus-transformed mouse cells. Virology 1981;108:251-5.
  21. Angelos JW, Marti E, Lazary S, Carmichael LE. Characterization of BPV-like DNA in equine sarcoids. Arch Virol 1991;119:95-109.
  22. Otten N, von Tscharner C, Lazary S, Antczak DF, Gerber H. DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. Arch Virol 1993;132:121-31.
  23. Lunardi M, de Alcantara BK, Otonel RA, Rodrigues WB, Alfieri AF, Alfieri AA. Bovine papillomavirus type 13 DNA in equine sarcoids. J Clin Microbiol 2013;51:2167-71.
  24. Martano M, Power K, Restucci B, Pagano I, Altamura G, Borzacchiello G. Expression of vascular endothelial growth factor (VEGF) in equine sarcoid. BMC Vet Res 2018;14:266.
  25. Corteggio A, Altamura G, Roperto F, Borzacchiello G. Bovine papillomavirus E5 and E7 oncoproteins in naturally occurring tumors: are two better than one?. Infect Agents Cancer 2013;8:1.
  26. Broström H, Fahlbrink E, Dubath ML, Lazary S. Association between equine leukocyte antigens (ELA) and equine sarcoid tumors in the population of Swedish halfbreds and some of their families. Vet Immunol Immunopathol 1988;19:215-23.
  27. Lazary S, Marti M, Szalai G, Gaillard C, Gerber H. Studies on the frequency and associations of equine leukocyte antigens in sarcoid and summer dermatitis. Anim Genet 1994;25:75-80.
  28. Christen G, Gerber V, Dolf G, Burger D, Koch C. Inheritance of equine sarcoid disease in Franches-Montagnes horses. Vet J 2014;199:68-71.
  29. Goodrich L, Gerber H, Marti E, Antczak DF. Equine sarcoids. Vet Clin North Am Equine Pract 1998;14:607-23.
  30. Jandova V, Klukowska-Rötzler J, Dolf G, Janda J, Roosje P, Marti E. Whole genome scan identifies several chromosomal regions linked to equine sarcoids. Schweiz Arch Tierheilkd 2012;154:19-25.
  31. Knottenbelt DC, Schumacher J, Toth F. Sarcoid transformation at wound sites. 2017;p. 490-507.
  32. Knottenbelt DC. The Equine sarcoid. Published in IVIS with the permission of the WEVA, 73-84.
  33. Haspeslagh M, Gerber V, Knottenbelt DC, Schüpbach G, Martens A, Koch C. The clinical diagnosis of equine sarcoids-Part 2: assessment of case features typical of equine sarcoids and validation of a diagnostic protocol to guide equine clinicians in the diagnosis of equine sarcoids. Vet J 2018;240:14-8.
  34. Koch C, Martens A, Hainisch EK, Schüpbach G, Gerber V, Haspeslagh M. The clinical diagnosis of equine sarcoids - Part 1: assessment of sensitivity and specificity using a multicentre case-based online examination. Vet J 2018;242:77-82.
  35. Bogaert L, Martens A, Depoorter P, Gasthuys F. Equine sarcoids-part 1: clinical presentation and epidemiology. Vlaams Diergeneeskundig Tijdschrift 2008;77:2-9.
  36. Knottenbelt DC, Snalune K, Kane JP. Sarcoids. 2015;11:203-19.
  37. Epperson ED, Castleman WL. Bovine papillomavirus DNA and S100 profiles in sarcoids and other cutaneous spindle cell tumors in horses. Vet Pathol 2017;54:44-52.
  38. Bogaert L, Martens A, Van Poucke M, Ducatelle R, De Cock H, Dewulf J. High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. Vet Microbiol 2008;129:58-68.
  39. Bogaert L, Heerden MV, Cock HE, Martens A, Chiers K. Molecular and immunohistochemical distinction of equine sarcoid from schwannoma. Vet Path 2011;48:737-41.
  40. Akgul B, Garcia-Escudero R, Ghali L, Pfister HJ, Fuchs PG, Navsaria H. The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res 2005;65:2216-23.
  41. Yuan Z, Gobeil PA, Campo MS, Nasir L. Equine sarcoid fibroblasts over-express matrix metalloproteinases and are invasive. Virology 2010;396:143-51.
  42. Martano M, Corteggio A, Restucci B, De Biase ME, Borzacchiello G, Maiolino P. Extracellular matrix remodeling in equine sarcoid: an immunohistochemical and molecular study. BMC Vet Res 2016;12:24.
  43. Bran GM, Goessler UR, Hormann K, Riedel F, Sadick H. Keloids: current concepts of pathogenesis (Review). Int J Mol Med 2009;24:283-93.
  44. López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000;19:4611-20.
  45. Li G, He L, Zhang E, Shi J, Zhang Q, Le AD. Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1a and VEGF expression in non-small cell lung cancer cells. Cancer Lett 2011;311:160-70.
  46. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know?. Br J Cancer 2009;100:865-9.
  47. Restucci B, Borzacchiello G, Maiolino P, Martano M, Paciello O, Papparella S. Expression of vascular endothelial growth factor receptor Flk-1 in canine mammary tumours. J Comp Pathol 2004;130:99-104.
  48. Restucci B, Maiolino P, Paciello O, Martano M, De Vico G, Papparella S. Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. J Comp Pathol 2003;128:252-9.
  49. Deschene K, Céleste C, Boerboom D, Theoret CL. Hypoxia regulates the expression of extracellular matrix associated proteins in equine dermal fibroblasts via HIF1. J Dermatol Sci 2012;65:12-8.
  50. Martano M, Altamura G, Power K, Restucci B, Carella F, Borzacchiello G. Evaluation of hypoxia-inducible factor-1 alpha (HIF-1α) in equine sarcoid: an immunohistochemical and biochemical study. Pathogens 2020;9:58.
  51. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008;15:621-7.
  52. Mählmann K, Hamza E, Marti E, Dolf G, Klukowska J, Gerber V. Increased FOXP3 expression in tumour-associated tissues of horses affected with equine sarcoid disease. Vet J 2014;202:516-21.
  53. Semik E, Gurgul A, Ząbek T, Ropka-Molik K, Koch C, Mählmann K. Transcriptome analysis of equine sarcoids. Vet Comp Oncol 2017;15:1370-1381.
  54. Wu MY, Kuo TY, Ho HN. Tumour-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer. J Formos Med Assoc 2011;110:580-6.
  55. Nixon C, Chambers G, Ellsmore V, Campo MS, Burr P, Argyle DJ. Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids. Cancer Lett 2005;221:237-45.
  56. Altamura G, Strazzullo M, Corteggio A, Francioso R, Roperto F, D'Esposito M. O(6)-methylguanine-DNA methyltransferase in equine sarcoids: molecular and epigenetic analysis. BMC Vet Res 2012;8:218.
  57. Strazzullo M, Corteggio A, Altamura G, Francioso R, Roperto F, D'Esposito M. Molecular and epigenetic analysis of the fragile histidine triad tumour suppressor gene in equine sarcoids. BMC Vet Res 2012;8:30.
  58. Johnston HM, Thompson H, Pirie HM. p53 immunohistochemistry in domestic animal tumours. Eur J Vet Pathol 1996;2:135-40.
  59. Martens A, De Moor A, Demeulemeester J, Ducatelle R. Histopathological characteristics of five clinical types of equine sarcoid. Res Vet Sci 2000;69:295-300.
  60. Bogaert L, Van Poucke M, De Baere C, Dewulf J, Peelman L, Ducatelle R. Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid. J Gen Virol 2007;88:2155-61.
  61. Finlay M, Yuan Z, Morgan IM, Campo MS, Nasir L. Equine sarcoids: bovine papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53. Vet Res 2012;43:81.
  62. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002;35:1431-40.
  63. Kukimoto I, Mori S, Sato H, Takeuchi T, Kanda T. Transcription factor human Skn-1a enhances replication of human papillomavirus DNA through the direct binding to two sites near the viral replication origin. FEBS J 2008;275:3123-35.
  64. Bogaert L, Van Poucke M, De Baere C, Peelman L, Gasthuys F, Martens A. Selection of a set of reliable reference genes for quantitative real-time PCR in normal equine skin and in equine sarcoids. BMC Biotechnol 2006;27(6):24.
  65. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
  66. Kamińska K, Nalejska E, Kubiak M, Wojtysiak J, Żołna Ł, Kowalewski J. Prognostic and predictive epigenetic biomarkers in oncology. Mol Diagn Ther 2019;23:83-95.
  67. Fardi M, Solali S, Farshdousti Hagh M. Epigenetic mechanisms as a new approach in cancer treatment: an updated review. Genes Dis 2018;5:304-11.
  68. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
  69. Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med 2019;25:403-18.
  70. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010;28:1069-78.
  71. Kulis M, Esteller M. DNA methylation in cancer. Adv Genet 2010;70:27-56.
  72. Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol 2018;58:187-207.
  73. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
  74. Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-5.
  75. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 2005;83:429-37.
  76. Neyaz MK, Kumar RS, Hussain S, Naqvi SH, Kohaar I, Thakur N. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers 2008;13:597-606.
  77. Semik-Gurgul E, Ząbek T, Fornal A, Gurgul A, Pawlina-Tyszko P, Klukowska-Rötzler J. Analysis of the methylation status of CpG sites within cancer-related genes in equine sarcoids. Ann Anim Sci 2018;18:907-18.
  78. Semik-Gurgul E, Ząbek T, Fornal A, Wnuk M, Pawlina-Tyszko K, Gurgul A. DNA methylation patterns of the S100A14, POU2F3 and SFN genes in equine sarcoid tissues. Res Vet Sci 2018;119:302-7.
  79. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res 2014;4:89-115.
  80. Semik E, Ząbek T, Gurgul A, Fornal A, Szmatoła T, Pawlina K. Comparative analysis of DNA methylation patterns of equine sarcoid and healthy skin samples. Vet Comp Oncol 2018;16:37-46.
  81. Potocki L, Lewinska A, Klukowska-Rötzler J, Bugno-Poniewierska M, Koch C, Mählmann K. DNA hypomethylation and oxidative stress-mediated increase in genomic instability in equine sarcoid-derived fibroblasts. Biochimie 2012;94:2013-24.
  82. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW. Induction of tumors in mice by genomic hipomethylation. Science 2003;300:489-92.
  83. Dellambra E, Golisano O, Bondanza S, Siviero E, Lacal P, Molinari M. Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. J Cell Biol 2000;149:1117-30.
  84. Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death. Differ. 2018;25:133-43.
  85. Lodygin D, Hermeking H. Epigenetic silencing of 14-3-3sigma in cancer. Semin Cancer Biol 2006;16:214-24.
  86. Li Z, Liu JY, Zhang JT. 14-3-3sigma, the double-edged sword of human cancers. Am J Transl Res 2009;1:326-40.
  87. Rodríguez-Jiménez FJ, Caldés T, Iniesta P, Vidart JA, Garcia-Asenjo JL, Benito M. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncol Rep 2007;17:1301-7.
  88. Yan J, Zhang J, Zhang X, Li X, Li L, Li Z. SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. Exp Cell Res 2018;364:125-32.
  89. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 2005;92:942-8.
  90. Kim NI, Kim G, Park MH, Lee JS, Yoon JH. Up-regulation of SPARC is associated with tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast carcinoma. Int J Clin Exp Pathol 2017;10:2675-88.
  91. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
  92. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013;105:452-8.
  93. Terron-Canedo N, Weir W, Nicolson L, Britton C, Nasir L. Differential expression of microRNAs in bovine papillomavirus type 1 transformed equine cells. Vet Comp Oncol 2017;15:764-74.
  94. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 2011;1809:668-77.
  95. Pawlina K, Gurgul A, Szmatoła T, Koch C, Mählmann K, Witkowski M. Comprehensive characteristics of microRNA expression profile of equine sarcoids. Biochimie 2017;137:20-8.
  96. Muralidhar G, Barbolina M. The miR-200 family: versatile players in epithelial ovarian cancer. Int J Mol Sci 2015;16:16833-47.
  97. Bogedale K, Jagannathan V, Gerber V, Unger L. Differentially expressed microRNAs, including a large microRNA cluster on chromosome 24, are associated with equine sarcoid and squamous cell carcinoma. Vet Comp Oncol 2019;17:155-64.
  98. Bogaert L, Martens A, Kast WM, Van Marck E, De Cock H. Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors. Vet Microbiol 2010;146:269-75.
  99. Unger L, Jagannathan V, Pacholewska A, Leeb T, Gerber V. Differences in miRNA differential expression in whole blood between horses with sarcoid regression and progression. J Vet Intern Med 2019;33:241-50.
  100. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008;105:7004-9.
  101. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer 2012;11:44.
  102. Sarver AL, Thayanithy V, Scott MC, Cleton-Jansen AM, Hogendoorn PC, Modiano JF. MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J Rare Dis 2013;8:7.
  103. Luk JM, Burchard J, Zhang C, Liu AM, Wong KF, Shek FH. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem 2011;286:30706-13.
  104. Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res 2014;20:3107-17.
  105. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-84.
  106. Unger L, Gerber V, Pacholewska A, Leeb T, Jagannathan V. MicroRNA fingerprints in serum and whole blood of sarcoid-affected horses as potential non-invasive diagnostic biomarkers. Vet Comp Oncol 2019;17:107-17.

Citations

This article has been cited 3 times.
  1. Semik-Gurgul E, Gurgul A, Szmatoła T. Transcriptome and methylome sequencing reveals altered long non-coding RNA genes expression and their aberrant DNA methylation in equine sarcoids. Funct Integr Genomics 2023 Aug 8;23(3):268.
    doi: 10.1007/s10142-023-01200-2pubmed: 37552338google scholar: lookup
  2. Pawlina-Tyszko K, Semik-Gurgul E, Ząbek T, Witkowski M. Methylation Status of Gene Bodies of Selected microRNA Genes Associated with Neoplastic Transformation in Equine Sarcoids. Cells 2022 Jun 14;11(12).
    doi: 10.3390/cells11121917pubmed: 35741046google scholar: lookup
  3. Podstawski P, Samiec M, Skrzyszowska M, Szmatoła T, Semik-Gurgul E, Ropka-Molik K. The Induced Expression of BPV E4 Gene in Equine Adult Dermal Fibroblast Cells as a Potential Model of Skin Sarcoid-like Neoplasia. Int J Mol Sci 2022 Feb 10;23(4).
    doi: 10.3390/ijms23041970pubmed: 35216085google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.